Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2019-12-05 Regulatory Filings
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2019
Regulatory Filings Classification · 99% confidence The document is titled "Company Announcement" and details a specific corporate event: achieving a USD 100 Million sales milestone in a collaboration. It includes key highlights, context, and contact information, typical of a press release or regulatory disclosure announcing material, non-financial news. It is not a full Annual Report (10-K), an Interim Report (IR), an Earnings Release (ER) focusing on P&L figures, or a formal Audit Report (AR). Since it is a specific, material announcement that doesn't fit the other specific categories (like DIRS, DIV, CAP, etc.), and it is a formal company communication, it best fits the general Regulatory Filings category (RNS) as a catch-all for material company news releases that aren't strictly financial reporting or meeting materials. The document length is substantial (over 12k characters), so it is the report itself, not just an announcement of a report (RPA). Given the nature of the announcement (milestone achievement), RNS is the most appropriate classification among the available options for a general corporate update.
2019-12-05 English
Genmab Achieves USD 100 Million Sales Milestone in DARZALEX® (daratumumab) Collaboration with Janssen
Regulatory Filings Classification · 99% confidence The document is titled 'Company Announcement' and details a specific corporate event: Genmab receiving a USD 100 Million milestone payment related to DARZALEX sales reaching USD 2.5 billion in a calendar year. It includes key financial/operational news, contact information, and forward-looking statements, typical of a press release or regulatory disclosure. Crucially, at the end, there is an 'Attachment' section with a link to download the actual filing document ('191205_CA57_Dara 2.5bn sales milestone'). According to Rule #2 (The 'MENU VS MEAL' Rule), when a document is short and announces that a report is attached or published, it should be classified as a Report Publication Announcement (RPA) rather than the underlying report itself (like ER or 10-K). Since this is an announcement about a corporate event/financial update that points to an attachment, RPA is the most appropriate classification, as it signals the publication of material information.
2019-12-05 English
6-K
Foreign Filer Report
2019-11-19 English
Genmab Announces European Marketing Authorization for DARZALEX® (Daratumumab) in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma
Regulatory Filings Classification · 95% confidence The document is a corporate announcement from Genmab regarding the European Commission's marketing authorization for a drug (DARZALEX). It follows the standard format of a press release or regulatory announcement, detailing the approval, the clinical study (MAIA), and background information on the company and the drug. It does not constitute a full financial report, audit, or proxy statement. As it is a general regulatory announcement regarding company operations and product approvals, it falls under the 'Regulatory Filings' category.
2019-11-19 English
Regulatory Filings 2019
Regulatory Filings Classification · 98% confidence The document is titled 'Company Announcement' and details the European Commission's marketing authorization for DARZALEX® based on Phase III MAIA study data. It includes company boilerplate information, contact details, and forward-looking statements, characteristic of a press release or official corporate disclosure. Since it is announcing a regulatory decision (approval) and providing context about the underlying clinical data, it functions as a general corporate update. It is not a full Annual Report (10-K), a specific financial supplement (XLSX), a formal Earnings Release (ER) focused purely on numbers, or a specific shareholder vote document. Given the nature of announcing a significant regulatory/commercial event, it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for official company announcements that don't fit more specific categories like DIV, CAP, or ER. The document length (14,550 chars) is substantial, ruling out a simple Report Publication Announcement (RPA) which typically just points to an attached report.
2019-11-19 English
Genmab Announces European Marketing Authorization for DARZALEX® (Daratumumab) in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma
Regulatory Filings Classification · 95% confidence The document is titled "Company Announcement" and details the European Commission's marketing authorization for DARZALEX® for treating multiple myeloma. It includes key highlights, study data references (Phase III MAIA study), and company information. This format—a concise announcement of a significant regulatory/commercial event, often released via a wire service (indicated by the structure and contact info)—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is announcing a specific regulatory approval and providing key context rather than being a full financial report (like 10-K or IR) or a transcript (CT), it fits best as an Earnings Release (ER) if it were tied to a reporting period, or a general announcement. Given the focus is purely on a regulatory/commercial milestone (drug approval) and not quarterly financial performance highlights, it leans towards a general regulatory announcement. However, in many financial databases, significant product/regulatory news that is not a mandated periodic report is often categorized as an Earnings Release (ER) if it impacts investor outlook, or RNS if it's purely informational. Since it is a formal announcement of a major event (drug approval) and not a standard periodic report, and it's not a proxy statement (DEF 14A) or a management discussion (MDA), RNS is the most appropriate general regulatory fallback, although ER is sometimes used for major commercial news. Given the context of a 'Company Announcement' detailing a major regulatory milestone, RNS (Regulatory Filings) is the safest general classification for non-periodic, material news that doesn't fit other specific categories like DIV or CAP.
2019-11-19 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.